Survodutide is one of the newer dual agonists in the GLP-1 pipeline — and it's generating serious attention in weight loss research. Developed by Boehringer Ingelheim, it targets both the GLP-1 receptor and the glucagon receptor. Phase 2 data showed up to 18.7% body weight reduction over 46 weeks — stronger than semaglutide, though trailing retatrutide's ~24%. Here's what you need to know.
What makes survodutide interesting isn't just the weight loss numbers. It's the mechanism. While tirzepatide grabbed headlines by pairing GLP-1 with GIP, survodutide took a different route: pairing GLP-1 with glucagon. These are very different second targets — and the downstream effects on metabolism, thermogenesis, and liver fat are meaningfully distinct.
 
The side effect profile is broadly similar to other GLP-1-class drugs, which is good and bad. Good because we know how to manage it. Bad because nausea in the early weeks is real.
Common (similar to semaglutide/tirzepatide):
Nausea — most common, peaks in the first 4-8 weeks then typically fades
Diarrhea
Vomiting
Constipation
Decreased appetite — this is the intended effect, but worth mentioning
Where it differs from tirzepatide/semaglutide:
The glucagon receptor activation introduces a specific consideration — glucagon raises blood sugar. The GLP-1 component largely counterbalances this, but the interplay is relevant for people with diabetes. Some trial participants also reported more pronounced early fatigue compared to tirzepatide cohorts, though this evened out after the initial titration phase.
 
The Dosage
Survodutide is still being investigated for its potential to aid weight loss, according to the data we have so far here are dose recommendations:
Starting dose: 1.6 – 2.4 mg
Maintenance dose: 4.8 mg – 6.0 mg
High dose: 6.0 mg +
If the current dose is working, there’s no need to raise it. Always aim for the lowest effective dosage increasing gradually if needed.